Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)
Fast, easy summary view of NICE guidance on 'familial hypercholesterolaemia'
NICE has developed diagnostics guidance on Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia. Diagnostics guidance is designed to help the NHS adopt efficient and cost-effective diagnostic technologies more rapidly and efficiently.
NICE has said that Elucigene FH20 and LIPOchip are not recommended for confirming familial hypercholesterolaemia because another test called comprehensive genetic analysis is more likely to accurately confirm the diagnosis at a reasonable cost.
NICE has also said that Elucigene FH20 and LIPOchip are not recommended for testing relatives of people with familial hypercholesterolaemia. Another test called targeted sequencing is more likely to accurately detect familial hypercholesterolaemia in these relatives and is less expensive.
- DG2 Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: familial hypercholesterolaemia
- None found
This page was last updated: 12 August 2013
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.